TABLE 1.

Postvaccination geometric mean titers

Yr, assay, strain, virus type	Value(s) for each treatment group				GMT ratio (95% CI)
	IIV-HD		IIV-SD
	N	GMT (95% CI)	N	GMT (95% CI)
HAI assays
2011–2012, HAI, A/California/7/2009 (H1N1), vaccine	2,375	481.75 (457.69, 507.07)	2,382	271.84 (257.40, 287.10)	1.77 (1.64, 1.91)
2011–2012, HAI, A/Victoria/210/2009 (H3N2), vaccine	2,375	685.53 (651.43, 721.42)	2,382	349.85 (332.09, 368.57)	1.96 (1.82, 2.11)
2011–2012, HAI, B/Brisbane/60/2008, vaccine	2,375	138.07 (132.16, 144.23)	2,382	97.55 (93.26, 102.03)	1.42 (1.33, 1.51)
2012–2013, HAI, A/California/7/2009 (H1N1), vaccine	2,879	406.95 (390.17, 424.45)	2,872	227.40 (216.85, 238.46)	1.79 (1.68, 1.91)
2012–2013, HAI, A/Victoria/361/2011 (H3N2), vaccine	2,879	459.97 (440.80, 479.96)	2,872	252.78 (241.64, 264.43)	1.82 (1.71, 1.94)
2012–2013, HAI, B/Texas/6/2011, vaccine	2,879	98.20 (94.52, 102.04)	2,872	61.79 (59.44, 64.22)	1.59 (1.51, 1.68)
2012–2013, HAI, A/Victoria/361/2011 (H3N2), circulating	317	49.60 (44.35, 55.47)	356	33.59 (30.04, 37.56)	1.48 (1.26, 1.73)
NT assays
2012–2013, NT, A/Victoria/361/2011 (H3N2), vaccine	318	218.3 (193.6; 246.0)	357	142.3 (126.1; 160.5)	1.53 (1.29; 1.82)
2012–2013, NT, A/Victoria/361/2011 (H3N2), circulating	318	506.7 (441.2; 581.9)	357	288.9 (249.3; 334.9)	1.75 (1.43; 2.15)
ELLA
2012–2013, N2 ELLA, N2 from A/Victoria/361/2011	318	54.55 (49.11; 60.59)	357	38.34 (34.49; 42.62)	1.42 (1.23; 1.65)